Alcon Inc. (SWX:ALCE)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 29.48B -2.7% |
| Revenue (ttm) | 9.16B +7.8% |
| Net Income | 555.67M -36.4% |
| EPS | 1.14 -34.7% |
| Shares Out | n/a |
| PE Ratio | 53.82 |
| Forward PE | 18.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100,000 |
| Open | 60.20 |
| Previous Close | 60.52 |
| Day's Range | 60.20 - 61.60 |
| 52-Week Range | 48.16 - 61.86 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About Alcon
Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company’s cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS... [Read more]
Financial Performance
In 2025, Alcon's revenue was $10.40 billion, an increase of 4.94% compared to the previous year's $9.91 billion. Earnings were $980.00 million, a decrease of -3.73%.
Financial numbers in USD Financial StatementsNews
Alcon price target raised to $63 from $62 at BofA
BofA raised the firm’s price target on Alcon (ALC) to $63 from $62 and keeps an Underperform rating on the shares after what the firm calls “another quarter that weakens…
Alcon price target lowered to $88.90 from $92.35 at Bernstein
Bernstein lowered the firm’s price target on Alcon (ALC) to $88.90 from $92.35 and keeps an Outperform rating on the shares following quarterly results. Q3 constant currency revenue growth was…
Alcon price target lowered to $87 from $90 at Baird
Baird lowered the firm’s price target on Alcon (ALC) to $87 from $90 and keeps an Outperform rating on the shares. The firm updated its model by trimming near-term estimates…
Alcon price target lowered to $65 from $70 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on Alcon (ALC) to $65 from $70 and keeps a Hold rating on the shares.
Alcon price target raised to $80 from $70 at Barclays
Barclays raised the firm’s price target on Alcon (ALC) to $80 from $70 and keeps an Equal Weight rating on the shares. The firm views the company’s Q3 report as…
Alcon: 3 Key Takeaways for Long-Term Investors
Alcon's defense of its premium lens franchise against competitor trials is the test that will decide whether its growth holds up.
Alcon Earnings Call Transcript: Q3 2026
Q3 sales grew 5% and core diluted EPS rose 15%; FY2026 guidance remains ~6% sales growth with narrower margin and EPS ranges. Competitive IOL pressure and low-end market growth are balanced by launches, premiumization and Neurotech.
Alcon Earnings release: Q3 2026
Alcon released its Q3 2026 earnings on November 11, 2026, summarizing the period's financial results.
Alcon Slides: Q3 2026
Alcon has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 11, 2026.
Alcon Quarterly report: Q3 2026
Alcon has published its Q3 2026 quarterly earnings report on November 11, 2026.
Alcon Q3 26 Earnings Conference Call At 8:00 AM ET
(RTTNews) - Alcon Inc. (ALC) will host a conference call at 8:00 AM ET on November 11, 2026, to discuss Q3 26 earnings results.
Alcon shares fall as tighter eye-care market outlook raises growth concerns
Alcon shares fall as tighter eye-care market outlook raises growth concerns
Alcon Q3 Profit Rises 10%; Tightens FY26 Outlook
(RTTNews) - Alcon Inc. (ALC), an eye care company offering surgical and vision care products, on Tuesday reported an increase in profit and revenues for the third quarter, driven largely by growth acr...
Alcon reports Q3 EPS 91c, consensus 89c
Reports Q3 revenue $2.71B, consensus $2.74B. “We remain on track for our 2026 objectives with year-to-date sales growth of six percent and double-digit core EPS growth, despite some specific areas…
Alcon narrows FY26 EPS growth view to 12%-14% from 12%-15%
Consensus $3.50. Narrows FY26 revenue growth view to 6% from up 5%-7%, consensus $11.08B.
Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth
GENEVA--(BUSINESS WIRE)--Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth.
Alcon (ALC) Surges 6.8%: Is This an Indication of Further Gains?
Alcon (ALC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
RxSight, Inc. Reports Third Quarter 2026 Financial Results
RxSight, Inc. reported total revenue of $24.6 million for the third quarter ended September 30, 2026, down 19% from the prior-year period, primarily reflecting ongoing competitive pressures. Revenue r...
Alcon price target lowered to $84 from $88 at KeyBanc
KeyBanc lowered the firm’s price target on Alcon (ALC) to $84 from $88 and keeps an Overweight rating on the shares. While the firm remains confident in visibility toward Alcon’s…
Alcon acquires Neurotech and expands retina portfolio with ENCELTO
Alcon (ALC) announced it has acquired Neurotech Pharmaceuticals, a company focused on developing innovative cell therapies for chronic and neurodegenerative eye diseases. This acquisition expands Alco...
Alcon Acquires Neurotech and ENCELTO, the Only FDA-Approved Treatment for MacTel Type 2
GENEVA--(BUSINESS WIRE)--Alcon Acquires Neurotech and ENCELTO, the Only FDA Approved Treatment for MacTel Type 2.
Alcon Secures FDA Approval For BRYTLY OTC Redness Relief Eye Drops
(RTTNews) - Alcon (ALC, ALC.SW) announced that the U.S. Food and Drug Administration approved BRYTLY Redness Reliever Eye Drops, an over-the-counter treatment designed to reduce eye redness.
Alcon announces FDA approval of Brytly Redness Reliever Eye Drops
Alcon (ALC) announced that the U.S. FDA has approved Brytly Redness Reliever Eye Drops. With one drop, Brytly works in just one minute to significantly reduce redness and delivers up…
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
GENEVA--(BUSINESS WIRE)--FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes.
FDA Approves Alcon's BRYTLY Redness Reliever Eye Drops for Up to 12 Hours of Whiter, Brighter-Looking Eyes
One drop works to significantly reduce redness, with results lasting up to 12 hours1 Lasts up to 50% longer than Lumify1-2,* Expands Alcon's portfolio of consumer eye care solutions and will be av...